We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Denovo Biopharma

News List

First Patient Dosed in Biomarker-Guided Study of DB102 for Newly-Diagnosed Glioblastoma americanpharmaceuticalreview
January 15, 2021
Denovo Biopharma announced dosing of the first patient in its biomarker guided Phase 3 clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma ...
Denovo Biopharma Announces Breakthrough Discovery of Liafensine for Depression americanpharmaceuticalreview
March 13, 2020
Denovo Biopharma has successfully discovered a novel genetic biomarker associated with DB104 response to treat depression using its proprietary biomarker discovery platform.
Denovo Biopharma Receives Global Rights to Novel Late-Stage Drug for Alzheimer's Disease americanpharmaceuticalreview
June 21, 2019
Denovo Biopharma has licensed ORM-12741 from Orion Corporation. Denovo gains global rights to develop, manufacture and commercialize ORM-12741.